- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.10. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.10. | Polyrizon Ltd.: Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy | 98 | GlobeNewswire (Europe) | Ra'anana, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture... ► Artikel lesen | |
| 19.09. | Polyrizon submits FDA pre-submission package for allergy nasal spray | 1 | Investing.com | ||
| 19.09. | Polyrizon Ltd.: Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker | 1 | GlobeNewswire (USA) | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 17.09. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.09. | Polyrizon reports positive preclinical results for nasal allergy blocker | 1 | Investing.com | ||
| 12.09. | Polyrizon meldet positive präklinische Ergebnisse für nasalen Allergie-Blocker | 1 | Investing.com Deutsch | ||
| 12.09. | Polyrizon Ltd.: Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study | 115 | GlobeNewswire (Europe) | Ra'anana, Israel, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| 04.09. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 14.08. | Polyrizon regains compliance with Nasdaq listing requirements | 2 | Investing.com | ||
| 14.08. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.08. | Polyrizon Ltd.: Polyrizon Regains Compliance with Nasdaq Listing Requirements | 289 | GlobeNewswire (Europe) | Ra'anana, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today... ► Artikel lesen | |
| 31.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.07. | Polyrizon Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 22.07. | Polyrizon Stock Jumps 53% On Positive Preclinical Results For Allergy Blocker | 1 | RTTNews | ||
| 22.07. | Polyrizon-Aktie steigt nach positiven Studiendaten für Allergie-Nasenspray stark an | 4 | Investing.com Deutsch | ||
| 22.07. | Polyrizon stock soars after promising nasal allergy blocker test results | 5 | Investing.com | ||
| 22.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.07. | Polyrizon meldet vielversprechende Ergebnisse für nasalen Allergenblocker | 2 | Investing.com Deutsch | ||
| 22.07. | Polyrizon's nasal allergy blocker shows promising deposition results | 1 | Investing.com |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| NOVAVAX | 7,147 | -0,31 % | Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU | ||
| 4SC | 0,844 | -1,86 % | PTA-News: 4SC AG: Telefonkonferenz am 17. Oktober 2025 zur Quartalsmitteilung Q3 2025 | DJ PTA-News: 4SC AG: Telefonkonferenz am 17. Oktober 2025 zur Quartalsmitteilung Q3 2025
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: Telefonkonferenz am 17. Oktober 2025 zur Quartalsmitteilung... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | Palatin Technologies, Inc.: Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim | Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,260 | +1,80 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,180 | 0,00 % | COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company's listing on the TSX TORONTO, ONTARIO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma... ► Artikel lesen | |
| XOMA ROYALTY | 33,400 | +6,37 % | XOMA Royalty Corporation Extends Tender Offer to Acquire LAVA Therapeutics N.V. | EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ: XOMA) and LAVA Therapeutics N.V. ("LAVA") (Nasdaq:... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 2,220 | -5,93 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| ORAGENICS | 1,380 | -1,43 % | Oragenics partners Receptor.AI for brain health candidate portfolio | ||
| LADRX | - | - | LadRx Corp - 8-K, Current Report | ||
| UNITY BIOTECHNOLOGY | 0,081 | -10,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 10.10.2025 | The following instruments on XETRA do have their last trading day on 10.10.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 10.10.2025ISIN NameDE000DB9U2Y9 DT.BANK IS. 20/25US44891CBN20... ► Artikel lesen | |
| TENAX THERAPEUTICS | 2,770 | -100,00 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF | Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also... ► Artikel lesen | |
| SERES THERAPEUTICS | 15,920 | -2,45 % | Seres Therapeutics, Inc.: Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway | Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem... ► Artikel lesen |
POLYRIZON LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -9,20 % bei einem Aktienkurs von 1,135 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.